Business Context and Reporting Period
Company: MaxLinear, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 3, 2013 (Event Date: October 4, 2013)
Context: The filing discloses a settlement agreement regarding patent litigation under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is a specific settlement payment.
- Settlement Payment: $1.25 million (one-time payment to Silicon Laboratories Inc.)
Material Changes
The material change reported is the resolution of outstanding patent litigation between MaxLinear, Inc. and Silicon Laboratories Inc. (Silicon Labs). Key terms include:
- Dismissal: All current litigation between the parties is dismissed with prejudice.
- Licensing: Mutual grant of worldwide, non-exclusive, royalty-free, and fully paid-up licenses to each other's entire patent portfolios.
- Scope: Licenses apply to existing products subject to litigation and future products substantially identical to those products.
- Release: Release of past infringement liability for both parties and their direct/indirect customers regarding the subject products.
- Non-Sue Agreement: Both parties agreed not to file patent infringement lawsuits against each other for three years from the settlement date.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) but does not contain forward-looking guidance or management commentary within the text provided.
Risks and Contingencies: The settlement eliminates the immediate risk of ongoing litigation costs and potential infringement liabilities between the two parties for the specified product scope and three-year period. The $1.25 million payment represents a resolved contingency.
Investor Verification Checklist
- Verify the impact of the $1.25 million settlement payment on the company's current quarter cash flow and earnings.
- Confirm the specific product lines covered by the "substantially identical" clause in the patent license to assess future freedom to operate.
- Review the attached press release (Exhibit 99.1) for any additional details on the litigation history or strategic implications not included in the 8-K text.
- Monitor the three-year non-sue period expiration date for potential future legal exposure.